Affiliation:
1. Hospital Regional de Alta Especialidad de Ciudad Victoria , Ciudad Victoria , Tamaulipas , Mexico
Abstract
Abstract
Introduction
COVID-19 leads to severe clinical complications that culminate in respiratory failure and acute respiratory distress syndrome (ARDS). Despite reports of some comorbidities that contribute to the development of COVID-19-mediated ARDS, there is great variation in mortality rates among critical COVID-19 patients in the world. To date, no studies have described the incidence and comorbidities associated with ARDS due to COVID-19 in the northeastern region of Mexico.
Aim of the study
To describe patients diagnosed with ARDS due to COVID-19 in the northeastern region of Mexico, as well as its variations in comparison with other regions of the country.
Material and Methods
We conducted a prospective and observational study in a tertiary care center in Northeastern Mexico. All patients diagnosed with SARS-CoV-2 infection and requiring management in the intensive care unit were included. We developed a database that was updated daily with the patients' demographic information, pre-existing diseases, disease severity, and clinical variables.
Results
The incidence of ARDS secondary to COVID-19 in HRAEV was high in comparison with other reports. Diabetes mellitus was the risk factor most associated with COVID-19-mediated ARDS.
Conclusion
Based on our findings and those previously reported in the literature, there are differences that we discuss between northeastern and central Mexico, and analyze other areas evaluated around the world.
Reference49 articles.
1. Gordo-Vidal F, Enciso-Calderón V. Síndrome de distrés respiratorio agudo, ventilación mecánica y función ventricular derecha [Acute respiratory distress syndrome, mechanical ventilation and right ventricular function]. Med Intensiva 2012;36(2):138–42.
2. Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet. (2022) 1; 400(10358):1157–70.
3. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. Lancet Respiratory Medicine. 2018;6(9): 691–8.
4. WeVent. Protocolo respiratorio de pacientes con SARS-CoV-2 (COVID-19). Disponible en: https://www.formacionsanitaria.eu/index.php/es/wevent?fbclid=IwAR3-v_7JY2K9IRInVOEIMy1uC5Lb28fML72Dsnrlt_eFHCRDHt1s5jZEmNY.
5. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes?. Intensive care medicine. 2020;46: 1099–1102.